Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/β-catenin signaling

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 437-445

  He, Bai Cheng ^a,b   Gao, Jian Li ^a   Luo, Xiaoji ^a,b   Luo, Jinyong ^a,b   Shen, Jikun ^b   Wang, Linyuan ^b   Zhou, Qixin ^a   Wang, Y I Tao ^c   Luu, Hue H ^b   Haydon, Rex C ^b   Wang, Chong Zhi ^d   Du, Wei ^d,e   Yuan, Chun Su ^d   He, Tong Chuan ^a,b,d   Zhang, Bing Qiang ^a,b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF MACAU   (Macao)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Colon cancer; Ginseng; Ginsenoside Rg3; Human colorectal cancer; Wnt signaling; catenin

Indexed keywords

BETA CATENIN; GINSENOSIDE RG 3; WNT PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 78651246162     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.858     Document Type: Article

References (81)

1. Labianca R, Beretta GD, Kildani B, et al: Colon cancer. Crit Rev Oncol Hematol 74: 106-133, 2010.
2. Cunningham D, Atkin W, Lenz HJ, et al: Colorectal cancer. Lancet 375: 1030-1047, 2010.
3. de la Chapelle A: Genetic predisposition to colorectal cancer. Nat Rev 4: 769-780, 2004.
4. Fearnhead NS, Wilding JL and Bodmer WF: Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 64: 27-43, 2002.
5. Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
6. Lynch HT and de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 348: 919-932, 2003.
7. Rowley PT: Inherited susceptibility to colorectal cancer. Annu Rev Med 56: 539-554, 2005.
8. da Rocha AB, Lopes RM and Schwartsmann G: Natural products in anticancer therapy. Curr Opin Pharmacol 1: 364-369, 2001.
9. Mann J: Natural products in cancer chemotherapy: past, present and future. Nat Rev 2: 143-148, 2002.
10. Cragg GM, Newman DJ and Snader KM: Natural products in drug discovery and development. J Nat Prod 60: 52-60, 1997.
11. Attele AS, Wu JA and Yuan CS: Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58: 1685-1693, 1999.
12. Chang YS, Seo EK, Gyllenhaal C and Block KI: Panax ginseng: a role in cancer therapy? Integ Cancer Ther 2: 13-33, 2003.
13. Christensen LP: Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 55: 1-99, 2009.
14. Wang CZ, Aung HH, Zhang B, et al: Chemopreventive effects of heat-processed Panax quinquefolius root on human breast cancer cells. Anticancer Res 28: 2545-2551, 2008.
15. Wang Y, Wang J, Yao M, et al: Metabonomics study on the effects of the ginsenoside Rg3 in a beta-cyclodextrin-based formulation on tumor-bearing rats by a fully automatic hydrophilic interaction/reversed-phase column-switching HPLC-ESI-MS approach. Anal Chem 80: 4680-4688, 2008.
16. Cho SH, Chung KS, Choi JH, Kim DH and Lee KT: Compound K, a metabolite of ginseng saponin, induces apoptosis via caspase-8-dependent pathway in HL-60 human leukemia cells. BMC Cancer 9: 449, 2009.
17. King M and Murphy L: Role of cyclin inhibitor protein p21 in the inhibition of HCT116 human colon cancer cell proliferation by American ginseng (Panax quinquefolius) and its constituents. Phytomedicine 17: 261-268, 2010.
18. Yoo JH, Kwon HC, Kim YJ, Park JH and Yang HO: KG-135, enriched with selected ginsenosides, inhibits the proliferation of human prostate cancer cells in culture and inhibits xenograft growth in athymic mice. Cancer Lett 289: 99-110, 2010.
19. Kim HS, Lee EH, Ko SR, Choi KJ, Park JH and Im DS: Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 27: 429-435, 2004.
20. Liu TG, Huang Y, Cui DD, et al: Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 9: 250, 2009.
21. Iishi H, Tatsuta M, Baba M, et al: Inhibition by ginsenoside Rg3 of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis 15: 603-611, 1997.
22. Kim SM, Lee SY, Cho JS, et al: Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol 631: 1-9, 2010.
23. Jia W, Bu X, Philips D, et al: Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 82: 431-437, 2004.
24. Kim YJ, Kwon HC, Ko H, et al: Anti-tumor activity of the ginsenoside Rk1 in human hepatocellular carcinoma cells through inhibition of telomerase activity and induction of apoptosis. Biol Pharmaceutical Bull 31: 826-830, 2008.
25. Lee KY, Lee YH, Kim SI, Park JH and Lee SK: Ginsenoside-Rg5 suppresses cyclin E-dependent protein kinase activity via up-regulating p21Cip/WAF1 and down-regulating cyclin E in SK-HEP-1 cells. Anticancer Res 17: 1067-1072, 1997.
26. Kim SM, Lee SY, Yuk DY, et al: Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res 32: 755-765, 2009.
27. Xie JT, Wang CZ, Zhang B, et al: In vitro and in vivo anticancer effects of american ginseng berry: exploring representative compounds. Biol Pharm Bull 32: 1552-1558, 2009.
28. Luo X, Wang CZ, Chen J, et al: Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. Int J Oncol 32: 975-983, 2008.
29. Luo X, Chen J, Song WX, et al: Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Laboratory investigation; a journal of technical methods and pathology 88: 1264-1277, 2008.
30. Su Y, Luo X, He BC, et al: Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin Exp Metastasis 26: 599-610, 2009.
31. He BC, Chen L, Zuo GW, et al: Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16: 2235-2245, 2010.
32. Luo X, Sharff KA, Chen J, He TC and Luu HH: S100A6 expression and function in human osteosarcoma. Clin Orthop Rel Res 466: 2060-2070, 2008.
33. Luu HH, Zhou L, Haydon RC, et al: Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett 229: 135-148, 2005.
34. Haydon RC, Zhou L, Feng T, et al: Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8: 1288-1294, 2002.
35. Luu HH, Kang Q, Park JK, et al: An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 22: 319-329, 2005.
36. Meng LH, Zhang H, Hayward L, Takemura H, Shao RG and Pommier Y: Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res 64: 9086-9092, 2004.
37. Luo Q, Kang Q, Si W, et al: Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279: 55958-55968, 2004.
38. Si W, Kang Q, Luu HH, et al: CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 26: 2955-2964, 2006.
39. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y and Ueno K: A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19: 1518-1520, 1996.
40. Stepanovic S, Vukovic D, Dakic I, Savic B and Svabic-Vlahovic M: A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40: 175-179, 2000.
41. Vajgand VJ and Mihajlovic R: Coulometric titration of bases in acetic acid and acetonitrile media. Talanta 16: 1311-1317, 1969.
42. He TC, Chan TA, Vogelstein B and Kinzler KW: PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345, 1999.
43. He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
44. Haydon RC, Deyrup A, Ishikawa A, et al: Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102: 338-342, 2002.
45. Jiang W, Zhou L, Breyer B, et al: Tetracycline-regulated gene expression mediated by a novel chimeric repressor that recruits histone deacetylases in mammalian cells. J Biol Chem 276: 45168-45174, 2001.
46. Sharff KA, Song WX, Luo X, et al: Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem 284: 649-659, 2009.
47. Tang N, Song WX, Luo J, et al: BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med 13: 2448-2464, 2009.
48. Zhou L, An N, Haydon RC, et al: Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 193: 161-170, 2003.
49. Zhou L, An N, Jiang W, et al: Fluorescence-based functional assay for Wnt/beta-catenin signaling activity. BioTechniques 33: 1126-1132, 2002.
50. Bi Y, Huang J, He Y, et al: Wnt antagonist SFRP3 inhibits the differentiation of mouse hepatic progenitor cells. J Cell Biochem 108: 295-303, 2009.
51. Huang J, Bi Y, Zhu GH, et al: Retinoic acid signalling induces the differentiation of mouse fetal liver-derived hepatic progenitor cells. Liver Int 29: 1569-1581, 2009.
52. Zhu GH, Huang J, Bi Y, et al: Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cells. Different Res Biol Diver 78: 195-204, 2009.
53. Chen L, Jiang W, Huang J, et al: Insulin-like growth factor 2 (IGF2) potentiates BMP9-induced osteogenic differentiation and bone formation. J Bone Miner Res (In press).
54. Korinek V, Barker N, Morin PJ, et al: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787, 1997.
55. Morin PJ, Sparks AB, Korinek V, et al: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in betacatenin or APC. Science 275: 1787-1790, 1997.
56. Sparks AB, Morin PJ, Vogelstein B and Kinzler KW: Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58: 1130-1134, 1998.
57. Chan TA, Wang Z, Dang LH, Vogelstein B and Kinzler KW: Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci USA 99: 8265-8270, 2002.
58. Benetti R, Copetti T, Dell'Orso S, et al: The calpain system is involved in the constitutive regulation of beta-catenin signaling functions. J Biol Chem 280: 22070-22080, 2005.
59. Luo J, Chen J, Deng ZL, et al: Wnt signaling and human diseases: what are the therapeutic implications? Laboratory investigation. J Tech Methods Pathol 87: 97-103, 2007.
60. Brocardo M, Nathke IS and Henderson BR: Redefining the subcellular location and transport of APC: new insights using a panel of antibodies. EMBO Rep 6: 184-190, 2005.
61. Ragnhammar P, Hafstrom L, Nygren P and Glimelius B: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol (Stockholm) 40: 282-308, 2001. (Pubitemid 32588124)
62. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. New Engl J Med 319: 525-532, 1988.
63. Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. Nature 396: 643-649, 1998.
64. Aaltonen LA, Peltomaki P, Leach FS, et al: Clues to the pathogenesis of familial colorectal cancer. Science 260: 812-816, 1993.
65. Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558-561, 1993.
66. Liu CX and Xiao PG: Recent advances on ginseng research in China. J Ethnopharmacol 36: 27-38, 1992.
67. Spelman K, Burns J, Nichols D, Winters N, Ottersberg S and Tenborg M: Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern Med Rev 11: 128-150, 2006.
68. Senchina DS, Shah NB, Doty DM, Sanderson CR and Hallam JE: Herbal supplements and athlete immune function-what's proven, disproven, and unproven? Exerc Immunol Rev 15: 66-106, 2009.
69. Song X and Hu S: Adjuvant activities of saponins from traditional Chinese medicinal herbs. Vaccine 27: 4883-4890, 2009.
70. Choi KT: Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin 29: 1109-1118, 2008.
71. Lu P, Su W, Miao ZH, Niu HR, Liu J and Hua QL: Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin J Integr Med 14: 33-36, 2008.
72. Block KI and Mead MN: Immune system effects of echinacea, ginseng, and astragalus: a review. Integ Cancer Ther 2: 247-267, 2003.
73. Zhang Q, Kang X, Yang B, Wang J and Yang F: Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. Cancer Biother Radiopharm 23: 647-653, 2008.
74. Yue PY, Wong DY, Wu PK, et al: The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol 72: 437-445, 2006.
75. Zhang Q, Kang X and Zhao W: Antiangiogenic effect of lowdose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun 342: 824-828, 2006.
76. Kang KS, Kim HY, Yamabe N, Park JH and Yokozawa T: Preventive effect of 20(S)-ginsenoside Rg3 against lipopolysaccharide-induced hepatic and renal injury in rats. Free Radic Res 41: 1181-1188, 2007.
77. Bae EA, Kim EJ, Park JS, Kim HS, Ryu JH and Kim DH: Ginsenosides Rg3 and Rh2 inhibit the activation of AP-1 and protein kinase A pathway in lipopolysaccharide/interferon-gamma-stimulated BV-2 microglial cells. Planta Medica 72: 627-633, 2006.
78. Kim ND, Kim EM, Kang KW, Cho MK, Choi SY and Kim SG: Ginsenoside Rg3 inhibits phenylephrine-induced vascular contraction through induction of nitric oxide synthase. Br J Pharmacol 140: 661-670, 2003.
79. Keum YS, Han SS, Chun KS, et al: Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat Res 523-524: 75-85, 2003.
80. Surh YJ, Na HK, Lee JY and Keum YS: Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer. J Korean Med Sci 16 (Suppl): S38-S41, 2001.
81. Li B, Wang CZ, He TC, Yuan CS and Du W: Antioxidants potentiate American ginseng-induced killing of colorectal cancer cells. Cancer Lett 289: 62-70, 2010.